Table 2.
IPTW-Hazard ratio (95% confidence interval) for hospitalization comparing SGLT2i (n=2492), GLP1RA (n=1982), and DPP4i (n=4762).
| Variable | SGLT2i vs. DPP4i (ref.) | GLP1RA vs. DPP4i (ref.) | SGLT2i vs. GLP1RA (ref.) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Unweighted no. of events (%) | IPTW-HR (95% CI) | Unweighted no. of events (%) | IPTW-HR (95% CI) | Unweighted no. of events (%) | IPTW-HR (95% CI) | ||||
| SGLT2i | DPP4i | GLP1RA | DPP4i | SGLT2i | GLP1RA | ||||
| All cause hospitalization | 329 (13%) | 1073 (23%) | 0.85 (0.75, 0.95)* | 369 (19%) | 1073 (23%) | 0.89 (0.78, 0.98)* | 329 (13%) | 369 (19%) | 0.92 (0.80, 1.07) |
| CVD hospitalization | 56 (2%) | 309 (7%) | 0.61 (0.47, 0.79)* | 89 (5%) | 309 (7%) | 0.77 (0.60, 0.99)* | 56 (2%) | 89 (5%) | 0.79 (0.58, 1.08) |
| MI hospitalization | 10 (0.4%) | 61 (1%) | 0.48 (0.25, 0.90)* | 19 (1%) | 61 (1%) | 0.79 (0.45,1.39) | 10 (0.4%) | 19 (1%) | 0.65 (0.30, 1.44) |
| HF hospitalization | 36 (1.4%) | 229 (5%) | 0.59 (0.41, 0.76)* | 73 (4%) | 229 (5%) | 0.84 (0.63, 1.11) | 36 (1.4%) | 73 (4%) | 0.66 (0.45, 0.95)* |
| Stroke hospitalization | 53 (2%) | 13 (0.5%) | 0.98 (0.56, 1.69) | 12 (0.6%) | 13 (0.5%) | 0.74 (0.39, 1.42) | 53 (2%) | 12 (0.6%) | 1.37 (0.63, 2.95) |
| Non-CVD hospitalization | 273 (11%) | 764 (16%) | 0.94 (0.83, 1.07) | 280 (14%) | 764 (16%) | 0.77 (0.60, 1.01) | 273 (11%) | 280 (14%) | 0.99 (0.84, 1.16) |
CVD=cardiovascular disease; DPP4i=dipeptidyl peptidase-4 inhibitors; HF=heart failure; GLP1RA= glucagon-like peptide 1 receptor agonists; IPTW=inverse probability of treatment weighting; MI=myocardial infarction; SGLT2i=sodium glucose-cotransporter 2 inhibitors.
*
The association was statistically significant (p<0.05).